SC
DSGN icon

SummitTX Capital’s Design Therapeutics DSGN Stock Holding History

SummitTX Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
+80,663
New +$1.01M 0.03% 431

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SummitTX Capital's DSGN Position: Q2 2026 in Review

SummitTX Capital opened a new position in Design Therapeutics (DSGN) in Q2 2026: 80,663 shares worth $1.17M. The stake represents 0.03% of the portfolio and ranks #431 among its holdings.

137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • SummitTX Capital held 80,663 shares of Design Therapeutics worth $1.17M as of Q2 2026.
  • Design Therapeutics was a new SummitTX Capital position in Q2 2026.
  • Design Therapeutics made up 0.03% of SummitTX Capital's portfolio in Q2 2026, its #431 holding.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.